You are here: Home » Current Affairs » Coronavirus » News
Business Standard

UK nod to Astra vaccine positive news, waiting for India's approval: SII

SII termed the approval for Oxford-AstraZeneca Covid-19 vaccine in the UK as encouraging news

Serum Institute of India | Coronavirus Vaccine

Press Trust of India  |  New Delhi 

Photo: Abhishek Waghmare
SII. Photo: Abhishek Waghmare

(SII) on Thursday termed the approval for Oxford-AstraZeneca COVID-19 vaccine in the UK as encouraging news and said that the company would now wait for the final nod for the medication in India.

Earlier in the day, the UK approved the COVID-19 vaccine developed by scientists at Oxford University and produced by AstraZeneca for human use, the second vaccine to be cleared for rollout in Britain after the Pfizer/BioNTech jabs.

The Oxford vaccine, which also has a tie-up with the SII, was being evaluated by the British regulator - the Medicines and Healthcare products Regulatory Agency (MHRA) - after the final cut of data was submitted by the government last week.

"This is great and encouraging news. We will wait for the final approval from Indian regulators," SII CEO Adar Poonawalla said in a statement.

In order to introduce an urgently needed vaccine against COVID-19 in India, SII, the world's largest vaccine manufacturer, has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.

The Pune-based company has applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation for COVID-19 vaccine in the country.

The company has already stockpiled around 50 million dosages of the vaccine and aims to produce up to 100 million dosages per month by March next year.

Besides SII, Bharat Biotech and Pfizer have also applied to the DCGI seeking emergency use authorisation for their COVID-19 vaccines.

The approval for the vaccine by the MHRA means the vaccine is both "safe and effective" and the government's Department of Health and Social Care (DHSC) said that the National Health Service (NHS) will prioritise giving the first of the two-dose vaccine to those in the most high-risk groups quickly.

The vaccine, codenamed AZD1222 or ChAdOx1 nCoV-19, was developed at Oxford University with support from the British-Swedish pharmaceutical giant AstraZeneca.

Britain has ordered 100 million doses of the Oxford jab, with 40 million expected to be available by the end of March.

ChAdOx1 nCoV-19 is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees, that has been genetically changed so that it is impossible for it to replicate in humans.

Once inside a human cell, the genetic instructions for the spike protein need to be "photocopied" many times, a process known as "transcription".

Once the spike protein is made, the immune system will react to it and this pre-trains the immune system to identify a real COVID-19 infection. So, when the person vaccinated is confronted with the SARS-CoV-2 virus, their immune system is pre-trained and ready to attack it.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, December 30 2020. 17:39 IST